[Plasminogen activator inhibitors from neoplastic tissues].
This article contains a survey of works, published in the last few years on plasminogen activators inhibitors in neoplastic tissues. These inhibitors belong to a heterogenous group of proteins, having different molecular weights and specific ways of acting. They exemplify immunological relationship to known inhibitors of fibrinolysis from normal tissues--i.e. the inhibitors from endothelial cells--(PAI-1) and placental inhibitor--(PAI-2). To PAI-1 type belong: acid-stabile inhibitor of fibrinolysis with Mr 50,000 from HTC hepatoma cells in rats, acid-labile inhibitor Mr 42,770 produced by HepG2 human hepatoma cells; the inhibitor with Mr 54,000 from HT 1080 human cells from fibrosarcoma and single-chain acid-stabile inhibitor with Mr 50,000 from MJZJ melanoma cells. In PAI-2 type we can mention the inhibitor with Mr 47,000 from U-937 histiocytic lymphoma cells.
Mirowski
M
M
Zakład Biochemii Instytutu Badania Srodowiska i Bioanalizy Akademii Medycznej w Lodzi.
Wierzbicki
R
R
D000818:Animals; D000933:Antifibrinolytic Agents / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000097:blood / Q000378:metabolism*; D010960:Plasminogen Activators / Q000096:biosynthesis*; D015849:Plasminogen Inactivators / Q000378:metabolism*; D051381:Rats; D010959:Tissue Plasminogen Activator / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000096:biosynthesis
D000933:Antifibrinolytic Agents; D015849:Plasminogen Inactivators; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
Inhibitory aktywatorów plazminogenu tkanek nowotworowych.